Private Equity Hub -- Arteriocyte, a commercial stage biotechnology company based in Cleveland, Ohio, has recieved $4.99 million from Ohio Third Frontier Commission’s Research Commercialization Program to expand clinical applications for its products. The company has received venture backing from DW Healthcare Partners.
